MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Biotechnology

Healthcare
$53.42 -1.54%

-$0.64 today

Market cap
$2.65B
Beta
0.75
P/E (TTM)
-22.0
EPS (TTM)
-$1.86
52W Low $9.43High $45.85

Volume 0.73M

Average 0.65M

MBX Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

MBX Biosciences, Inc. Common StockNASDAQ: MBX

Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Free cash flow growth accelerates

Q3 FY2026 free cash flow of $36.07M (cash outflow) rose 64.4% year over year, ahead of the +25.9% change in trailing-twelve-month free cash flow. Sequentially, it rose 53.3% from the prior quarter. Over 3 fiscal years it compounded at +51.5% a year.

Context

  • Free cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +64.4% holds above the trailing-twelve-month pace of +25.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$36.07M+53.3% QoQ
Last fiscal yearDec 2025
-$81.88M+47.4% YoY
LTMSep 2026
-$99.33M+25.9% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+64.4%——
1 year+47.4%——
3-year CAGR+51.5%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(81.88M) USD
Year-over-year change
-47.4%

Free Cash Flow vs competitors

How MBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +25.9% is the 4th highest of 8, against a peer median of -10.4%.
  • Over three fiscal years its annual growth of +51.5% compares with a peer median of +2.5%.
MBX Competitors
Free Cash Flow for MBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASNDAscendis Pharma A/SLTM Sep 2026€516.87M EUR+560.9%—42.8%
VKTXViking Therapeutics, Inc.LTM Jun 2026$418.44M USD+174.3%+79.2%—
KLRAKailera Therapeutics, Inc.FY2025$122.3M USD———
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$99.33M USD+25.9%+51.5%—
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$83.24M USD-23.7%-13.1%29.6%
ALTAltimmune, Inc.LTM Mar 2026$71.97M USD-10.4%+2.5%199908.3%
BMEABiomea Fusion, Inc.LTM Mar 2026$56.25M USD-50.6%+3.5%—
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$47.23M USD+272.2%—15.0%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$8.74M USD-16.5%-27.6%—
Peer median (excluding MBX) —-10.4%+2.5%36.2%

Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.14M)(32.56M)(61.92M)(86.97M)
Depreciation & Amortization56K157K244K248K
Deferred Income Tax0000
Stock-Based Compensation306K2.04M5.22M8.68M
Change in Working Capital1.29M(735K)4.6M1.58M
Accounts Receivables0000
Inventory0000
Accounts Payables671K412K3.93M(2.46M)
Other Working Capital619K(1.15M)670K4.03M
Other Non-Cash Items1.36M(880K)(2.82M)(3.48M)
Operating Cash Flow(23.12M)(31.98M)(54.68M)(79.95M)
Capital Expenditures(441K)(129K)(874K)(1.93M)
Acquisitions (Net)0000
Purchases of Investments(20.22M)(63.8M)(239.47M)(358.15M)
Sales of Investments9.25M33M79.75M267.87M
Other Investing Activities0008.5M
Investing Cash Flow(11.41M)(30.93M)(160.6M)(83.71M)
Debt Repayment10M000
Common Stock Issued30K739K174.54M189.59M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(428K)(30K)(3.94M)0
Financing Cash Flow46.06M69.22M234.1M189.59M
Effect of Forex Changes0000
Net Change in Cash11.53M6.31M18.83M25.94M
Free Cash Flow(23.56M)(32.11M)(55.56M)(81.88M)

MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Intrinsic Alpha fair value

Locked

Current Price

$53.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.